Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy (Journal article)
Tzaida, O./ Gogas, H./ Dafni, U./ Kyroudi, A./ Papaspyrou, I./ Kyriakou, V./ Malamou-Mitsi, V./ Alamani, M./ Skopa, C./ Kostopoulos, I./ Kastritis, E./ Pectasides, D./ Briasoulis, E./ Kalofonos, H. P./ Aravantinos, G./ Fountzilas, G./ Arapantoni-Dadioti, P.
BACKGROUND: To assess the prognostic and predictive significance of HER-1/EGFR protein levels in high-risk patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy. METHODS: 595 high-risk breast cancer patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF). Disease-free survival (DFS) was the primary end point. HER-1/EGFR was assessed by immunohistochemistry (IHC) in 312 patients. RESULTS: HER-1/EGFR expression was detected in 54 of 312 patients (17%). Positive expression of HER-1/EGFR was significantly associated with negative receptor status (52 vs. 17%, p < 0.001), worse histological grade (70 vs. 45%, p = 0.001), HER-2 overexpression (46 vs. 27%, p = 0.01) and positive p53 expression (48 vs. 19%, p < 0.001). With a median follow-up of 7 years, the total number of relapses was 105 (34%), and the total number of deaths 69 (22%). The analysis for DFS provides significant evidence that the HER-1/EGFR effect on the risk of disease progression was different according to treatment (interaction p = 0.02). Regarding overall survival, a trend towards a significant difference for an interaction of HER-1/EGFR and treatment was found (p = 0.07). CONCLUSION: The present study demonstrated a differential effect of positive HER-1/EGFR expression in the two treatment groups, with HER-1/EGFR being a negative prognostic marker in the absence of paclitaxel.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Adult,Aged,Antineoplastic Combined Chemotherapy Protocols/*administration & dosage,Breast Neoplasms/drug therapy/*genetics/metabolism/mortality,Chemotherapy, Adjuvant,Combined Modality Therapy,Cyclophosphamide/administration & dosage,Disease-Free Survival,Epirubicin/*administration & dosage,Female,Fluorouracil/administration & dosage,Genes, erbB-1/*genetics,Humans,Immunohistochemistry,Methotrexate/administration & dosage,Middle Aged,Paclitaxel/*administration & dosage,Predictive Value of Tests,Prognosis|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
|Tzaida-2007-Evaluation of the pr.pdf||326.31 kB||Adobe PDF||View/Open Request a copy|
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.